FDA approved an at-home induction option for risankizumab-rzaa in adults with moderate-to-severe Crohn's disease, based on the phase 3 AFFIRM trial.
|Articles|September 1, 2002
- Pharmaceutical Executive-09-01-2002
Top European Trial Sponsors
A CenterWatch survey of 545 European clinical trial investigators named the best pharma companies to work with in clinical development.
Advertisement
A CenterWatch survey of 545 European clinical trial investigators named the best pharma companies to work with in clinical development. Bayer, Lilly, Pharmacia, and AstraZeneca were listed as the top sponsors for their attentive study monitoring, realistic protocol design, and improved staff training. The survey rated more than 30 European pharma companies.
Articles in this issue
about 24 years ago
Pharmaceutical Innovation Under Attackabout 24 years ago
More Statins = Fewer Heart Attacksabout 24 years ago
When Worlds Collideabout 24 years ago
Novo Nordisk Cancels Clinical Trialsabout 24 years ago
Dutch Government Just Says Noabout 24 years ago
Lilly Marketers Cross the Lineabout 24 years ago
Spending Hits a Wallabout 24 years ago
Strangers in the Shadowsabout 24 years ago
Plants and Patentsabout 24 years ago
Industry Audit & Companies of the YearAdvertisement
Related to this article
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.
Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
Gilead agrees to acquire an oral IL-23R inhibitor from PepStar, while Zymeworks licenses its DLL3-targeting T cell engager ZW209 to Roche.
Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while AI Proteins has enters a collaboration with Astellas to design novel miniprotein therapeutics.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
2
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
3
Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act
4
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
5